These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25297720)

  • 1. Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications.
    Hoglund RM; Byakika-Kibwika P; Lamorde M; Merry C; Ashton M; Hanpithakpong W; Day NP; White NJ; Äbelö A; Tarning J
    Br J Clin Pharmacol; 2015 Apr; 79(4):636-49. PubMed ID: 25297720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
    Byakika-Kibwika P; Lamorde M; Mayito J; Nabukeera L; Namakula R; Mayanja-Kizza H; Katabira E; Ntale M; Pakker N; Ryan M; Hanpithakpong W; Tarning J; Lindegardh N; de Vries PJ; Khoo S; Back D; Merry C
    J Antimicrob Chemother; 2012 Sep; 67(9):2213-21. PubMed ID: 22687893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients.
    Kredo T; Mauff K; Workman L; Van der Walt JS; Wiesner L; Smith PJ; Maartens G; Cohen K; Barnes KI
    BMC Infect Dis; 2016 Jan; 16():30. PubMed ID: 26818566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.
    Huang L; Carey V; Lindsey JC; Marzan F; Gingrich D; Graham B; Barlow-Mosha L; Ssemambo PK; Kamthunzi P; Nachman S; Parikh S; Aweeka FT;
    PLoS One; 2017; 12(10):e0186589. PubMed ID: 29065172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
    Kakuda TN; DeMasi R; van Delft Y; Mohammed P
    HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.
    Kredo T; Mauff K; Van der Walt JS; Wiesner L; Maartens G; Cohen K; Smith P; Barnes KI
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5616-23. PubMed ID: 21947399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.
    German P; Parikh S; Lawrence J; Dorsey G; Rosenthal PJ; Havlir D; Charlebois E; Hanpithakpong W; Lindegardh N; Aweeka FT
    J Acquir Immune Defic Syndr; 2009 Aug; 51(4):424-9. PubMed ID: 19506482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy.
    Banda CG; Dzinjalamala F; Mukaka M; Mallewa J; Maiden V; Terlouw DJ; Lalloo DG; Khoo SH; Mwapasa V
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.
    Parikh S; Kajubi R; Huang L; Ssebuliba J; Kiconco S; Gao Q; Li F; Were M; Kakuru A; Achan J; Mwebaza N; Aweeka FT
    Clin Infect Dis; 2016 Aug; 63(3):414-22. PubMed ID: 27143666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.
    Parikh S; Fehintola F; Huang L; Olson A; Adedeji WA; Darin KM; Morse GD; Murphy RL; Taiwo BO; Akinyinka OO; Adewole IF; Aweeka FT; Scarsi KK
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7852-6. PubMed ID: 26392500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers.
    Huang L; Parikh S; Rosenthal PJ; Lizak P; Marzan F; Dorsey G; Havlir D; Aweeka FT
    J Acquir Immune Defic Syndr; 2012 Nov; 61(3):310-6. PubMed ID: 22918158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.
    Byakika-Kibwika P; Lamorde M; Okaba-Kayom V; Mayanja-Kizza H; Katabira E; Hanpithakpong W; Pakker N; Dorlo TP; Tarning J; Lindegardh N; de Vries PJ; Back D; Khoo S; Merry C
    J Antimicrob Chemother; 2012 May; 67(5):1217-23. PubMed ID: 22316571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.
    Kay K; Goodwin J; Ehrlich H; Ou J; Freeman T; Wang K; Li F; Wade M; French J; Huang L; Aweeka F; Mwebaza N; Kajubi R; Riggs M; Ruiz-Garcia A; Parikh S
    Clin Pharmacol Ther; 2023 Mar; 113(3):660-669. PubMed ID: 36260349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
    Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM
    Malar J; 2015 Apr; 14():179. PubMed ID: 25906774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects.
    Lefèvre G; Carpenter P; Souppart C; Schmidli H; McClean M; Stypinski D
    Br J Clin Pharmacol; 2002 Nov; 54(5):485-92. PubMed ID: 12445027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of lopinavir/ritonavir on the antimalarial activity of artemether or artemether/lumefantrine in a mouse model of Plasmodium berghei.
    Abiodun OO; Akinbo J; Ojurongbe O
    J Chemother; 2015 Feb; 27(1):25-8. PubMed ID: 24621166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment.
    Francis J; Barnes KI; Workman L; Kredo T; Vestergaard LS; Hoglund RM; Byakika-Kibwika P; Lamorde M; Walimbwa SI; Chijioke-Nwauche I; Sutherland CJ; Merry C; Scarsi KK; Nyagonde N; Lemnge MM; Khoo SH; Bygbjerg IC; Parikh S; Aweeka FT; Tarning J; Denti P
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.
    Hughes E; Mwebaza N; Huang L; Kajubi R; Nguyen V; Nyunt MM; Orukan F; Mwima MW; Parikh S; Aweeka F
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):140-147. PubMed ID: 31929402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria.
    Usman SO; Oreagba IA; Akinyede AA; Agbaje EO; Akinleye MO; Onwujuobi AG; Ken-Owotor C; Adeuja O; Ogunfowokan T; Kogbe S; Owolabi ET; Adeniji H; Busari AW; Hassan OO; Abideen G; Akanmu AS
    J Pharmacol Sci; 2020 Nov; 144(3):95-101. PubMed ID: 32921396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the pharmacokinetics of Coartem.
    Djimdé A; Lefèvre G
    Malar J; 2009 Oct; 8 Suppl 1(Suppl 1):S4. PubMed ID: 19818171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.